Pharmacological Treatment of Patients with Mild to Moderate COVID-19: A Comprehensive Review
Int J Environ Res Public Health,. 2021 Jul 5;18(13):7212. doi: 10.3390/ijerph18137212.
Reinaldo B Bestetti 1, Rosemary Furlan-Daniel 1, Vinicius M R Silva 1
| Placebo-controlled | Bamlanivimab +etesivimab | Reduced viral load |
| Open-label | Inhaled Budesonide | hospitalization and number of visits to emergency department |
| Placebo-controlled | Vitamin D | Reduced viral load |
| Open-label | Favirapir | Shortened time to cure |
| Open-label | Interferon beta-1 +Lopinavir + Ritonavir. | Shortened time to viral clearance |
| Placebo-controlled | Colchicine | Reduced the composite endpoint of death or hospitalization |
| Placebo-controlled | Fluvoxamine | Reduced clinical deterioration |
| Placebo-controlled | Nitazoxamide | Reduced viral load |
| Placebo-controlled | Ivermectine | May have shortened time to viral clearance |
| Placebo-controlled | Levamisole | May reduce clinical symptoms |
| Open-label | Hypertonic saline | Reduced clinical symptoms |
| Open-label | Remdesivir | Improved clinical status |
| Placebo-controlled | REGN-COV2 | Decreased viral load and improved clinical status |
| Placebo-controlled | Peginterferon lambda | Decreased viral load |
Ivermectin and COVID-19
COVID-19 risks reduced by Vitamin D, Magnesium, Zinc, Resveratrol, Omega-3, etc. (auto-updated)
COVID-19 doctors not allowed to use treatments that work - Dr McCullough Video and transcript May 2021
After 57 years FDA is declaring NAC to be a drug (note: 16 trials are investigating NAC ability to fight COVID-19) – June 2021
AI is examining 170,000 potential COVID-19 treatments, Vitamin D is one of only 6 found – Sept 4, 2020
Vitamin D is amoung the many treatments that can also prevent
COVID-19 treated by Vitamin D - studies, reports, videos
- As of Aug 1, the page had: 34 trials, 6 trial results, 21 meta-analyses and reviews, 62 observations, 34 recommendations, 55 associations, 89 speculations, 45 videos see related: Governments, HealthProblems, Hospitals, Dark Skins, 26 risk factors are ALL associated with low Vit D, Recent Virus pages Fight COVID-19 with 50K Vit D weekly Vaccine problems
Vitamin D meta-analyses for VIRUS
- COVID-19 5X more likely to be severe if low vitamin D (23 studies) – 13th meta-analysis July 2021
- Severe COVID-19 3.5 more likely if low vitamin D (30 studies) – meta-analysis July 2021
- COVID-19 patients who had supplemented with Vitamin D were 3X less likely to enter ICU – June 2021
- COVID-19 mortality 3X more likely if low vitamin D (999,179 people) – meta-analysis March 29, 2021
- COVID-19 was 2.6X more severe if very low Vitamin D (43 studies) – meta-analysis March 26, 2021
- Low Vitamin D associated with 2.7X more severe COVID-19 – 12th MA March 5, 2021
- Vitamin D supplementation fights COVID-19 – 11th meta-analysis Jan 24, 2021
- 3.7 X less likely to die of COVID-19 if supplemented with Vitamin D - meta-analysis Jan 5, 2021
- Less likely to test positive for COVID-19 if higher Vitamin D – meta-analysis Jan 6, 2021
- Vitamin D reduces COVID-19 by 80 percent - anonymous meta-analysis - Jan 5, 2021
- COVID-19 1.7X more likely to be severe if low Vitamin D - meta-analysis Oct 2020
- Low Vitamin D associated 1.8X increased risk of COVID-19 death in hospital – meta-analysis Nov 4, 2020
- Acute viral respiratory infections reduced by Vitamin D - overview of 20 reviews - Aug 2020
- Prudent to consider that Vitamin D has a role in COVID-19 – meta-analysis – Aug 7, 2020
- Risk of enveloped virus infection is increased 50 percent if poor Vitamin D Receptor - meta-analysis Dec 2018
- Hepatitis B patients have 2 ng lower level of Vitamin D – meta-analysis June 2019
- Influenza Vaccination not benefited by lowish levels of vitamin D – meta-analysis March 2018
RecoveryTrial.net is trying many (prescription) treatments
Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin,: Convalescent plasma, Tocilizumab. Immunoglobulin, Synthetic neutralising antibodies, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, Infliximab, High Dose Corticosteroid
Suspect they are funded by Big Pharma - virtually all are patented and required a prescription
Download the PDF from Vitamin D Life
Mild to moderate COVID-19 can be found in about 80% of patients. Although mortality is low, mild to moderate COVID-19 may progress to severe or even critical stages in about one week. This poses a substantial burden on the health care system, and ultimately culminates in death or incapacitation and hospitalization. Therefore, pharmacological treatment is paramount for patients with this condition, especially those with recognized risk factors to disease progression. We conducted a comprehensive review in the medical literature searching for randomized studies carried out in patients with mild to moderate COVID-19. A total of 14 randomized studies were identified, enrolling a total of 6848 patients. Nine studies (64%) were randomized, placebo-controlled trials, whereas five were open-label randomized trials (35%). We observed that Bamlanivimab and nitazoxanide reduced viral load, whereas ivermectin may have shortened time to viral clearance; Interferon Beta-1 reduced time to viral clearance and vitamin D reduced viral load; Favirapir, peginterferon, and levamisole improved clinical symptoms, whereas fluvoxamine halted disease progression; inhaled budesonide reduced the number of hospitalizations and visits to emergency departments; colchicine reduced the number of deaths and hospitalizations. Collectively, therefore, these findings show that treatment of early COVID-19 may be associated with reduced viral load, thus potentially decreasing disease spread in the community. Moreover, treatment of patients with mild to moderate COVID-19 may also be associated with improved clinical symptoms, hospitalization, and disease progression. We suggest that colchicine, inhaled budesonide, and nitazoxanide, along with nonpharmacological measures, based on efficacy and costs, may be used to mitigate the effects of the COVID-19 pandemic in middle-income countries.